25Jul 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

This study investigated whether adding the XPO1 inhibitor selinexor to intensive chemotherapy would improve outcomes in this population. 102 AML patients > 65 years of age were randomly assigned to standard chemotherapy (3 + 7) with or without oral selinexor 60 mg twice weekly, days 1–24. In the second cycle, cytarabine 1000 mg/m2 twice daily, days 1–6, with or without selinexor was given. CR/CRi rates were significantly higher in the control arm than in the investigational arm. AML and infectious complications accounted for an increased death rate in the investigational arm. Irrespective of treatment, MRD status appeared to be correlated with survival after two cycles. This study concludes that adding selinexor to standard chemotherapy negatively affects the therapeutic outcome of elderly AML patients.

  • #oncology

Like

Save

Share